NCT00222144已完成2 期
Phase II Study of Gleevec and Taxotere in Recurrent Non-Small Cell Lung Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 23
- 试验地点
- 2
- 主要终点
- Response rate
研究概览
简要总结
The primary goal of this study is to determine the effects of the combination of Gleevec and Taxotere in lung cancer in terms of control and reduction of the cancer size. The study will also test lung cancer to see if the presence of certain protein called receptor for platelet derived growth factor can influence the effect of the treatment.
详细描述
The purpose of this study is to evaluate the response rate of Gleevec with Taxotere in patients with recurrent non-small cell lung cancer. Also to determine the expression of PDGF-R, phosphorylated PDGF-r and C-kit in the original tissue and correlate with response. If the patient has a tumor in an accessible location, we will ask for consent from the patient to obtain biopsy before and after the therapy to assess the same molecular markers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •One prior chemotherapy treatment: use of single chemotherapy or a regimen containing more than one drug. Regimen must have a platinum agent (cisplatin or carboplatin). Prior biological treatment won't be counted as chemotherapy treatment. Chemoradiation or prior induction or adjuvant chemotherapy +/- chemoradiation will constitute one prior chemotherapy regimen. Patients may not have received Docetaxel. Taxol as part of initial therapy is allowed.
- •Documented recurrent/progressive disease by radiographic exam (CT scan, MRI, bone scan or CXR), clinical exam (presence of palpable nodes) or biopsy.
- •No signs of clinically active brain metastasis or spinal cord compression. If patient has brain metastasis or cord compression, patient will be eligible if stable without deterioration of performance status after radiation therapy and off corticosteroids.
- •Cases with pleural effusion must have another site of disease for measurement and follow-up.
- •ECOG performance status 0-1
- •Bi-dimensional measurable disease (≥ 1 cm by CT or other radiogram; physical exam alone is permissible if there is no radiographically measurable tumor)
- •Laboratory: ANC ≥ 1,500/mm3, Hemoglobin > 8g/dl, platelet ≥ 100,000/mm3, Total Bilirubin ≤ 1.5 mg/dl, Creatinine ≤ 2.0 mg/dl, Transaminase (AST/ALT) ≤ 2.5 X upper normal limit if ALK phosphatase is ≤ Upper normal limit OR ALK may be up to 4X ULN if transaminase are ≤ ULN.
- •Age ≥ 18 years old
- •Histologic or cytologic diagnosis of NSCLC, biopsy at diagnosis or on recurrence. Histology may include large cell, squamous cell, undifferentiated, bronchioalveolar or adenocarcinoma but not small cell lung cancer or mixed small and non-small cell lung cancer, or carcinoid. Mixed histology non-small cell lung cancer will be allowed, i.e.: large cell neuroendocrine carcinoma.
- •IHC of the biopsy specimen, if available, for PDGF-R. Insufficient tissue will not preclude study enrollment.
- •FEV1>800 cc
排除标准
- •ECOG performance status 2 or worse
- •Psychological, familial, sociological or geographical conditions, which prevent weekly medical follow-up or compliance with the study protocol
- •Radiation to more than 30% of bone marrow
- •More than 1 different prior cytotoxic chemotherapy regimen
- •Co-Morbid condition that would affect survival: grade III/IV cardiac problems as defined by New York Heart Association (e.g. end-stage congestive heart failure, myocardial infarction within 6 months of study), random uncontrolled blood sugar ≥300 mg/dl, unstable angina, active infection on antibiotics, FEV1 less than 800 cc, patient with known chronic liver disease (i.e., chronic active hepatitis and cirrhosis)
- •Use of investigational agents or chemotherapy within 4 weeks
- •Pregnant or nursing women and women or men with reproductive potential unless using effective contraception throughout study and for 3 months after discontinuation of study drug.
- •No other active invasive cancer. Patient is < 5 years free of another malignancy except for: other primary malignancy isn't currently clinically significant or requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
- •Patients with a history of hypersensitivity to taxane, Polysorbate 80 or gemcitabine and who could not tolerate treatment even with 24 H premedication with Decadron and Benadryl. (If the patient had prior hypersensitivity, but did not receive 24 H premedication for taxane, the patient may be eligible if he/she tolerates one cycle with 24 H premedication).
- •Existing peripheral neuropathy CTC Version 3> grade 2
- •Patient has known diagnosis of human immunodeficiency virus (HIV) infection
- •Patients who can not take oral medication. Percutaneous gastrostomy feeding tube will be allowed if Gleevec can be given through PEG
- •Patient who had major surgery within 2 weeks prior to study entry
研究组 & 干预措施
1
Experimental
Gleevec and Taxotere
干预措施: Gleevec and Taxotere (Drug)
结局指标
主要结局
Response rate
时间窗: Every 2 cycles of therapy and followup
次要结局
- Time to progression, survival and correlation of PDGF and PDGFR with outcome.(Baseline, at completion of therapy, 12 months)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
2 期
Gleevec and Gemzar in Patients With Epithelial Ovarian CancerPrimary Peritoneal CancerOvarian CancerNCT00928642Henry M. Jackson Foundation for the Advancement of Military Medicine8
已完成
2 期
A Study of Gemzar, Taxotere, and Xeloda for Adjuvant Pancreatic CancerPancreatic CancerNCT00882310Columbia University37
已完成
1 期
Study of Gemcitabine/Taxotere/Xeloda (GTX) in Combination With Cisplatin and Irinotecan in Subjects With Metastatic Pancreatic CancerMetastatic Pancreatic AdenocarcinomaNCT02324543Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins47
已完成
1 期
Phase II Study of Taxotere in Combination With Exisulind in Non-Small Cell Lung Cancer (NSCLC) PatientsNSCLCNCT00072618Astellas Pharma Inc52
已完成
2 期
Gemcitabine/Taxotere/Xeloda (GTX) With Cisplatin in Subjects With Metastatic Pancreatic CancerPancreatic CancerNCT01459614Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins44